Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
NextRNA Therapeutics was founded in 2020 to pursue non-coding RNAs as a new class of therapeutic target for diseases including cancer, infectious diseases, and autoimmune disorders. There are many RNAs that do not make proteins, called non-coding RNAs (ncRNA). These ncRNAs are able to regulate essential processes and when altered cause disease. NextRNA has developed […]
Anturec Pharmaceuticals is a German anticancer drug development company which was founded in 2020 based on research carried out at University Hospital Muenster. The company’s target is aminopeptidase N (CD13) located on cells of the tumor vasculature and some tumor cells, but absent from most mature blood vessels. The company’s founders have designed and studied […]
Founded in 2020, Signet Therapeutics is developing targeted small molecule cancer drugs using novel disease models. Dr. Haisheng Zhang, CEO of Signet Therapeutics, and his core team members originate from Dana-Farber Cancer Institute, Harvard Medical School. The company says that traditional in vitro studies use cell lines that cannot accurately model patient’s drug performance, often […]